D. McGuire

Comparison of standard carbidopa–levodopa and sustained‐release carbidopa–levodopa in parkinson's disease: Pharmacokinetic and quality‐of‐life measures

K. Lyons, R. Pahwa, W. Koller, 1997, Movement disorders : official journal of the Movement Disorder Society.

Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease

A. Tröster, K. Lyons, R. Pahwa, 1997, Clinical neuropharmacology.

Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

C. Ayers, P. Wang, X. Li, 2022, Frontiers in Pharmacology.

Early morning akinesia in Parkinson's disease

K. Lyons, R. Pahwa, J. Hubble, 1996, Neurology.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease

L. Seeberger, E. Siemers, C. Adler, 2001, Neurology.

Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study

K. Lyons, R. Pahwa, W. Koller, 1996, Movement disorders : official journal of the Movement Disorder Society.

G.O.17 Results of a phase 2 open-label study of ISIS-SMNRx in patients with infantile (Type 1) spinal muscular atrophy

R. Finkel, C. Bennett, J. Montes, 2014, Neuromuscular Disorders.

G.O.18 Results of a phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy

S. Iannaccone, K. Swoboda, C. Bennett, 2014, Neuromuscular Disorders.